Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,051Revenue $M198Net Margin (%)-6.9Z-Score11.8
Enterprise Value $M2,922EPS $-0.4Operating Margin %-2.6F-Score7
P/E(ttm))0Cash Flow Per Share $-2.0Pre-tax Margin (%)-6.9Higher ROA y-yY
Price/Book17.410-y EBITDA Growth Rate %0Quick Ratio1.3Cash flow > EarningsY
Price/Sales15.05-y EBITDA Growth Rate %0Current Ratio1.5Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-5.5Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)4ROE % (ttm)-12.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M36.2ROI % (ttm)-53.4Gross Margin Increase y-yY

Gurus Latest Trades with PCRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PCRXMariko Gordon 2014-12-31 Reduce-0.54%$86.02 - $107.8
($94.65)
$ 84.20-12%Reduce -15.33%689,628
PCRXGeorge Soros 2014-12-31 Buy 0.08%$86.02 - $107.8
($94.65)
$ 84.20-12%New holding87,000
PCRXJoel Greenblatt 2014-12-31 Sold Out -0.01%$86.02 - $107.8
($94.65)
$ 84.20-12%Sold Out0
PCRXKen Fisher 2014-12-31 Buy $86.02 - $107.8
($94.72)
$ 84.20-12%New holding4,800
PCRXMariko Gordon 2014-09-30 Reduce-1.21%$83.31 - $108.26
($97.65)
$ 84.20-16%Reduce -28.09%814,470
PCRXRon Baron 2014-09-30 Reduce-0.03%$83.31 - $108.26
($97.65)
$ 84.20-16%Reduce -59.75%62,139
PCRXJoel Greenblatt 2014-09-30 Reduce$83.31 - $108.26
($97.65)
$ 84.20-16%Reduce -26.78%6,946
PCRXMariko Gordon 2014-06-30 Reduce-0.66%$63.61 - $91.01
($75.89)
$ 84.2010%Reduce -17.39%1,132,552
PCRXRon Baron 2014-06-30 Add0.05%$63.61 - $91.01
($75.89)
$ 84.2010%Add 802.88%154,393
PCRXJoel Greenblatt 2014-06-30 Buy 0.01%$63.61 - $91.01
($75.89)
$ 84.2010%New holding9,486
PCRXMariko Gordon 2014-03-31 Add0.19%$55.83 - $80.43
($67.63)
$ 84.2020%Add 5.13%1,371,042
PCRXRon Baron 2014-03-31 Add$55.83 - $80.43
($67.63)
$ 84.2020%Add 163.28%17,100
PCRXMariko Gordon 2013-12-31 Add2.08%$47.74 - $56.97
($52.53)
$ 84.2038%Add 203.52%1,304,190
PCRXRon Baron 2013-12-31 Buy $47.74 - $56.97
($52.53)
$ 84.2038%New holding6,495
PCRXMariko Gordon 2013-09-30 Add0.93%$30.01 - $47.47
($36.37)
$ 84.2057%Add 3812.66%429,688
PCRXMariko Gordon 2013-06-30 Buy 0.02%$25.84 - $30.26
($28.93)
$ 84.2066%New holding10,982
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PCRX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


PCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HASTINGS PAUL JDirector 2015-04-10Sell2,500$884.99view
Riker Lauren BullaroExecutive Director, Finance 2015-03-16Sell5,000$95.34-3.09view
PACE GARY WDirector 2015-03-13Buy1,000$93.83-1.53view
LONGENECKER JOHN P PHDDirector 2015-03-12Sell3,000$95.28-3.03view
Scibetta James SSVP, CFO 2015-02-06Sell15,000$111.22-16.93view
STACK DAVID MPresident, CEO and Chairman 2015-01-15Sell15,000$97.52-5.26view
HASTINGS PAUL JDirector 2015-01-12Sell2,500$94.06-1.78view
LONGENECKER JOHN P PHDDirector 2014-12-29Sell1,000$93.32-1view
WINGER DENNIS LDirector 2014-12-05Buy2,645$94.54-2.27view
Markvicka TauniaSVP, Chief Commercial Officer 2014-11-07Buy230$86.626.66view

Press Releases about PCRX :

    Quarterly/Annual Reports about PCRX:

    News about PCRX:

    Articles On GuruFocus.com
    Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
    SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Pacira Pharmace Nov 28 2014 
    Mariko Gordon's First Quarter Top Five May 15 2014 
    Baron Funds Comments on Pacira Pharmaceuticals Mar 05 2014 
    comment on PCRX Mar 15 2013 
    Weekly CFO Buys Highlight: PCRX, UGI, MIG, GLT, IOSP Feb 28 2011 
    Weekly CFO Buys Highlight: REFR, UGI, PCRX, NOIZ Feb 21 2011 
    Pacira Pharmaceuticals Inc. (PCRX) CFO James S Scibetta buys 5,000 Shares Feb 17 2011 
    Pacira Pharmaceuticals Inc. (PCRX) CEO David M Stack buys 5,000 Shares Feb 11 2011 


    More From Other Websites
    Pacira Announces Encouraging Data on Lead Drug Exparel - Analyst Blog Apr 13 2015
    Pacira Pharmaceuticals Announces Timing for First Quarter 2015 Financial Results Webcast and... Apr 13 2015
    Pacira Pharmaceuticals Announces Timing for First Quarter 2015 Financial Results Webcast and... Apr 13 2015
    Pacira Announces New Data on Health Economic Benefits of EXPAREL for Postsurgical Pain Control... Apr 10 2015
    Pacira Announces New Data on Health Economic Benefits of EXPAREL for Postsurgical Pain Control... Apr 10 2015
    Pacira Announces Data Reinforcing Benefits of EXPAREL® for Postsurgical Pain Control Following... Mar 26 2015
    Pacira Announces Data Reinforcing Benefits of EXPAREL® for Postsurgical Pain Control Following... Mar 26 2015
    New Data Demonstrate Reduced Opioid Requirements Following Use of EXPAREL in Hysterectomy and... Mar 23 2015
    New Data Demonstrate Reduced Opioid Requirements Following Use of EXPAREL in Hysterectomy and... Mar 23 2015
    Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference Mar 04 2015
    Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference Mar 04 2015
    Pacira Pharmaceuticals Plunges on FDA's CRL for Exparel - Analyst Blog Mar 03 2015
    PACIRA PHARMACEUTICALS, INC. Financials Mar 03 2015
    PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 02 2015
    Lumber Liquidators and Endo are big market movers Mar 02 2015
    Pacira Pharma slumps after FDA ruling on pain drug Mar 02 2015
    Pacira Pharma slumps after FDA ruling on pain drug Mar 02 2015
    Pacira Receives Complete Response Letter from FDA for sNDA Seeking Approval of EXPAREL® Use in... Mar 02 2015
    FDA rejects Pacira's application for expanded use of pain drug Mar 02 2015
    Pacira Receives Complete Response Letter from FDA for sNDA Seeking Approval of EXPAREL® Use in... Mar 02 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK